300119 Tianjin Ringpu Bio-Technology
- 15.42
- -0.11-0.71%
Tianjin Ringpu Bio-Technology News
Ruipu Biotech (300119.SZ): As of May 20, 2024, the total number of shareholders of the company was about 20,000
Gelonghui, May 23 | Ruipu Biotech (300119.SZ) said on the investor interactive platform that as of May 20, 2024, the total number of shareholders of the company was about 20,000.
Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Looks Interesting, And It's About To Pay A Dividend
Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) stock is about to trade ex-dividend in four days. Typically, the ex-dividend date is one business day before the record date which is the date on
Ruipu Biotech (300119.SZ) plans to pay 4 yuan for 10 shares to be deducted from interest on May 15
Ruipu Biotech (300119.SZ) announced that the company's 2023 equity distribution plan: every 10 shares to all shareholders...
Ruipu Biology (300119.SZ): The main business areas are R&D, production and sales of veterinary biological products, veterinary pharmaceutical preparations (chemicals, Chinese veterinary drugs, disinfectants, etc.), veterinary raw materials, and veterinary
Gelonghui, May 7 | Ruipu Biotech (300119.SZ) said on the investor interactive platform that Ruipu Biotech is a high-tech enterprise serving the animal health industry. Its main business areas are R&D, production, sales of veterinary biological products, veterinary pharmaceutical preparations (chemicals, Chinese veterinary drugs, disinfectants, etc.), veterinary APIs, and the provision of overall animal disease prevention and control solutions. It is one of the largest and most comprehensive veterinary drug companies in China. It is also a major national animal disease prevention and control vaccine manufacturer. After rapid development, Chinese animal insurance enterprises have basically achieved success in the field of economic animals
Ruipu Biology (300119.SZ): It has a synthetic biotechnology platform with many leading technologies such as gene editing, gene synthesis, cell modification, and multiomics
Gelonghui, May 7 | Ruipu Biology (300119.SZ) said on the investor interactive platform that the company has a synthetic biotechnology platform, which has many leading technologies such as gene editing, gene synthesis, cell modification, protein mining and modification, high-throughput screening, high-throughput analysis, and multiomics, which has promoted the upgrading of the company's synthetic biotechnology in veterinary vaccines, antibody drugs, enzyme preparations, probiotics, and related intermediates. The company has continued to establish research institutes and colleges such as the Tianjin Institute of Industrial Biotechnology of the Chinese Academy of Sciences and Shanghai Jiaotong University
Reipu Biotech (300119.SZ): In the future, it is planned to launch products such as oral insect repellents, cat fever monoclonal antibodies, canine quadruplets, etc.
Gelonghui, April 26, 丨 Ruipu Biotech (300119.SZ) held a performance briefing on April 25, 2024, to discuss “What is the current channel development situation in the pet sector and the channel side plans for this year? What big products are worth looking forward to?” The company replied that the company has set up nearly 100 core dealers in all provinces and cities across the country, covering major Tier 1 and 2 cities across the country, and has covered more than 5,000 channel stores nationwide. In 2024, the company will continue to optimize dealers and sink channels to prefecture-level markets; form a mutually beneficial and win-win mechanism with core dealers, deepen cooperation and bonds; and strengthen
Ruipu Biotech (300119.SZ): This year, the company also plans to market a live recombinant H5 vaccine against duck fever, as well as several Chinese veterinary drugs such as bacteriophages and Xubiying extract
Gelonghui, April 26, 丨 Ruipu Biotech (300119.SZ) held a performance briefing on April 25, 2024 to discuss “What major products will the company launch in the poultry sector in the past two years?” The company replied that in the poultry sector, the company focuses on multivalent multivalent vaccines, original pharmaceutical preparations, Chinese veterinary medicine products, etc. Recently, the company received three new veterinary drug certificates for the triple inactivated vaccine (LaSota strain+TJ-4 strain+RP-8-c strain), and Avian Adenovirus (H9 subtype), and aims to launch it on the market this year. In addition, the company also plans to go public and restructure Duck Fever this year
Reipu Biotech (300119.SZ): The cat triple vaccine was launched at the end of January this year, with cumulative sales of about 12 million yuan in the first quarter
Gelonghui April 26 | Ruipu Biotech (300119.SZ) held a performance briefing on April 25, 2024 to discuss “The current promotion status of the triple vaccine for cats?” The company replied that the triple vaccine for cats was launched at the end of January this year, with cumulative sales of about 12 million yuan in the first quarter, and the terminals covered 4,600 pet hospitals. Up to now, there have been no cases of side effects of the triple vaccine for cats. The safety and efficacy have reached the expected level, and it has gradually developed a reputation among pet hospitals and pet owners. During the reporting period, “Rui Meow Shu” was the only officially designated vaccine for the FiFe China Cat Race. It was a professional cat racing cat
Ruipu Biotech (300119.SZ): As of April 19, 2024, the number of shareholders of the company was more than 18,000
Gelonghui, April 24 | Ruipu Biotech (300119.SZ) said on the investor interactive platform that as of April 19, 2024, the number of shareholders of the company was more than 18,000.
Ruipu Biotech (300119.SZ): As of April 10, 2024, the number of shareholders of the company was more than 18,000
Gelonghui, April 12 | Ruipu Biotech (300119.SZ) said on the investor interactive platform that as of April 10, 2024, the number of shareholders of the company was more than 18,000.
Investors Shouldn't Be Too Comfortable With Tianjin Ringpu Bio-TechnologyLtd's (SZSE:300119) Earnings
Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) stock was strong after they recently reported robust earnings. However, we think that shareholders may be missing some concerning details in the
Ruipu Biotech (300119.SZ): As of February 29, 2024, the number of shareholders of the company was more than 17,000
Gelonghui, April 1 | Ruipu Biotech (300119.SZ) said on the investor interactive platform that as of February 29, 2024, the number of shareholders of the company was more than 17,000.
Ruipu Biotech (300119.SZ): Net profit for 2023 increased by 30.64% to 453 million yuan, plans to pay 10 to 4 yuan
Gelonghui, March 29丨Ruipu Biotech (300119.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 2,249 billion yuan, an increase of 7.90%; net profit attributable to shareholders of listed companies was 453 million yuan, an increase of 30.64% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 318 million yuan, an increase of 13.43% year on year; basic income per share was 0.9772 yuan; it plans to distribute a cash dividend of 4 yuan (tax included) for every 10 shares to all shareholders.
Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
With its stock down 15% over the past three months, it is easy to disregard Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119). But if you pay close attention, you might find that its key financial indi
A Look At The Fair Value Of Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119)
Key Insights Using the Dividend Discount Model, Tianjin Ringpu Bio-TechnologyLtd fair value estimate is CN¥11.48 Tianjin Ringpu Bio-TechnologyLtd's CN¥13.75 share price indicates it is trading at si
Ruipu Biotech (300119.SZ): As of February 20, 2024, the number of shareholders of the company was more than 17,000
Gelonghui, Feb. 21丨Ruipu Biotech (300119.SZ) said on the investor interactive platform that as of February 20, 2024, the number of shareholders of the company was more than 17,000.
Ruipu Biotech (300119.SZ): Currently, the dog quadruple vaccine has completed clinical trials and is applying for a new veterinary drug registration certificate
Gelonghui, Feb. 20: An investor asked Ruipu Biotech (300119.SZ) on the investor interactive platform, “Can the dog quadruple vaccine obtain a registration batch number in the first half of this year?” The company replied that the dog quadruple vaccine has now completed clinical trials and is applying for a new veterinary drug registration certificate. The company will disclose the subsequent approval status of the new veterinary drug in the form of an interim announcement. Please pay attention to the company's announcements on the Shenzhen Stock Exchange website and Juchao Information Network.
Ruipu Biotech (300119.SZ): As of January 31, 2024, the number of shareholders of the company was around 17,700
Gelonghui, February 2 | Ruipu Biotech (300119.SZ) said on the investor interactive platform that as of January 31, 2024, the number of shareholders of the company was around 17,700.
Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Has A Pretty Healthy Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
Ruipu Biotech (300119.SZ): A total cost of 59.99 million yuan to buy back 0.79% of the shares
Gelonghui, January 26, 丨 Ruipu Biotech (300119.SZ) announced that as of January 25, 2024, the company had repurchased a total of 3,689,608 shares of the Company's shares through centralized bidding transactions, accounting for 0.7913% of the company's total share capital. The lowest transaction price was RMB 13.78 per share, the highest transaction price was RMB 17.55 per share, and the total amount paid was RMB 59,992,513.11. The company's share repurchase plan has been implemented. The actual repurchase period is from October 27, 2023 to 2024/1
Analysis
Price Target
No Data
